Delivery Order SPE2DB20D1004-SPE2DB24FF5N1

Award Date 3/6/24
Potential Completion Date 3/7/24
Potential Value $1.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order (SPE2DB25FPJMH) issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,202.94 fixed-price contract is for the delivery of 1,000 units of Tamsulosin HCl 0.4 mg capsules, a medication used to treat an enlarged prostate. The contract has an ultimate completion date of November 19, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,583.25 firm fixed-price delivery order is for the supply of Tamsulosin HCl 0.4 mg capsules, a medication used to treat an enlarged prostate. The contract has a completion date of November 8, 2024 and was awarded on November 7, 2022. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,796.09, is a Firm Fixed Price Delivery Order for the supply of 1,000 capsules of Tamsulosin HCl 0.4 mg, a medication used to treat enlarged prostate. The contract has a completion date of December 20, 2024 and was awarded on December 19, 2024. AmerisourceBergen also holds a $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,148.70 firm fixed price delivery order is for the supply of 1,000 capsules of Tamsulosin HCl 0.4 mg, a medication used to treat benign prostatic hyperplasia. The award has an ultimate completion date of November 25, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,566,707,544 units of Tamsulosin HCL 0.4 mg capsules. The firm-fixed-price, $1,667.08 delivery order contract has an ultimate completion date of December 13, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award, valued at $2,923.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication used to treat benign prostatic hyperplasia. The contract is a firm-fixed-price delivery order with an ultimate completion date of October 28, 2024. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $9,067.03 under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC). The contract is for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, a medication used to treat symptoms of an enlarged prostate. This order does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant...
This federal contract award, valued at $2,076.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,564,616,825 units of Tamsulosin Hydrochloride 0.4 mg capsules, a medication used to treat an enlarged prostate. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,572.06 Firm Fixed Price Delivery Order is for the supply of 4,561,952,911 units of Tamsulosin HCl 0.4 mg capsules. The contract has an ultimate completion date of August 28, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award, issued by the Defense Logistics Agency (DLA) Troop Support Medical, is for the delivery of 1,000 units of Tamsulosin HCL 0.4 mg capsules. The $4,297.74 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a completion date of December 12, 2023 and was not set aside for any specific business type. AmerisourceBergen holds a significant $999,999,999 Indefinite...
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB24FF5N1
    Delivery Order

This federal contract award, valued at $1,769.49, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,563,880,250 units of Tamsulosin HCl 0.4 mg capsules, a drug used to treat an enlarged prostate. The contract has a firm fixed price and will run through March 7, 2024.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 2/27/25, 10:08 AM